Literature DB >> 17610320

Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide.

Murray B Urowitz1, Dominique Ibañez, Yaser Ali, Dafna D Gladman.   

Abstract

OBJECTIVE: To assess outcomes in patients with lupus nephritis treated with immunosuppressives compared to those treated with cyclophosphamide in a cohort study and in a matched cohort study.
METHODS: Patients with active renal disease treated with immunosuppressive/cytotoxic medications were selected from the University of Toronto Lupus Clinic database. Five outcomes were evaluated: all-cause mortality, renal failure, reversal of active renal disease, relapse of active renal disease, and toxicity.
RESULTS: There were no differences in the outcomes of death, renal failure, reversal or relapse of active renal disease, or toxicity in those using or not using cyclophosphamide.
CONCLUSION: Antimetabolites should be considered standard of care for patients with lupus nephritis both for induction and for maintenance therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17610320

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

Review 1.  Lupus nephritis in Colombians: contrasts and comparisons with other populations.

Authors:  Juan-Manuel Anaya; Carlos Cañas; Rubén D Mantilla; Ricardo Pineda-Tamayo; Gabriel J Tobón; Catalina Herrera-Diaz; Diego M Rendón; Adriana Rojas-Villarraga; Mauricio Uribe
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

2.  ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry.

Authors:  Xana Kim-Howard; Amit K Maiti; Juan-Manuel Anaya; Gail R Bruner; Elizabeth Brown; Joan T Merrill; Jeffrey C Edberg; Michelle A Petri; John D Reveille; Rosalind Ramsey-Goldman; Graciela S Alarcon; Timothy J Vyse; Gary Gilkeson; Robert P Kimberly; Judith A James; Joel M Guthridge; John B Harley; Swapan K Nath
Journal:  Ann Rheum Dis       Date:  2009-11-25       Impact factor: 19.103

3.  Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review.

Authors:  A Oglesby; A J Shaul; T Pokora; C Paramore; L Cragin; G Dennis; S Narayanan; A Weinstein
Journal:  Int J Rheumatol       Date:  2013-04-03

4.  Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

Authors:  George K Bertsias; Maria Tektonidou; Zahir Amoura; Martin Aringer; Ingeborg Bajema; Jo H M Berden; John Boletis; Ricard Cervera; Thomas Dörner; Andrea Doria; Franco Ferrario; Jürgen Floege; Frederic A Houssiau; John P A Ioannidis; David A Isenberg; Cees G M Kallenberg; Liz Lightstone; Stephen D Marks; Alberto Martini; Gabriela Moroni; Irmgard Neumann; Manuel Praga; Matthias Schneider; Argyre Starra; Vladimir Tesar; Carlos Vasconcelos; Ronald F van Vollenhoven; Helena Zakharova; Marion Haubitz; Caroline Gordon; David Jayne; Dimitrios T Boumpas
Journal:  Ann Rheum Dis       Date:  2012-07-31       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.